SB-649868
- Generic Name
- SB-649868
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24FN3O3S
- CAS Number
- 380899-24-1
- Unique Ingredient Identifier
- 1L1V1K2M4V
- Background
SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT01030939
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00534872
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00495729
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Disturbed Sleep Model Study.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00440323
- Locations
- 🇬🇧
GSK Investigational Site, Guildford, Surrey, United Kingdom
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00426816
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath